Tim Allsopp

Tim Allsopp has extensive experience in the field of regenerative medicine and stem cell science. Tim is currently working as the CTO at Laverock Therapeutics since 2022. Before this, they served as the Managing Director of Consilium Bio Ltd starting from 2017. Tim also worked as a Consultant for various not-for-profit international public funding agencies and foundations since 2003, where they specialized in stem cell subjects and supported R&D innovations in regenerative medicine.

In addition, Tim has held significant positions at other renowned organizations. Tim was the Founder and CTO of a company affiliated with Tropic Biosciences from 2020 to 2022, where they combined gene silencing with cell therapy. Tim also served as the Royal Society Industry Expert In Residence at the University of Cambridge from 2019 to 2022. Prior to this, Tim worked at Pfizer Ltd as the Head of Stem Cells & Cell Therapy Lead at Neusentis, where they led the stem cell team and developed iPS for disease modeling, phenotypic assay development, and cell therapy workstream development. Tim also worked as an IMI Project Coordinator for the European Bank for induced pluripotent stem cells at Pfizer, where they coordinated a public-private partnership on research use of induced pluripotent stem cells.

Earlier in their career, Tim held the position of Head of External Research at Neusentis, a Pfizer research unit, where they assessed and analyzed cell therapy assets and technologies. Tim was also the CSO at Stem Cell Sciences plc from 2000 to 2009.

Overall, Tim Allsopp's work experience reflects their expertise in stem cell science, regenerative medicine, and leadership in the field.

From 1984 to 1988, Tim Allsopp studied at the University of London. During this time, they pursued a B.Sc. and PhD degree in the fields of Zoology, Biophysics, Cell & Molecular Biology.